Aprepitant versus dexamethasone for delayed emesis: What is the role of the 5-hydroxytryptamine type 3 receptor antagonist palonosetron?

摘要

To the Editor: We would like to comment on the recently published study by Roila et al1 and to respond to the authors' discussion of our own work. The hypothesis underlying the study was that in the pivotal trial by Warr et al,2 aprepitant had proved superior to ondansetron against delayed emesis as the result of a carryover effect on the protection against acute emesis caused by an anthracycline plus cyclophosphamide (AC). The current superiority trial,1 which was prematurely closed because of accrual difficulties, suggests that either aprepitant or dexamethasone can be recommended, but because of the lower cost of corticosteroids, dexamethasone should be chosen as prophylaxis for delayed emesis caused by AC.